InvestSMART

Tetratherix Limited (ASX: TTX) - Share Price

- Current share price for TTX : $6.060

Tetratherix Limited (TTX) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a Company that is engaged in development programs in the areas of regenerative medicine and commercialising medical device technology across multiple applications including Bone Regeneration, Tissue Spacing and Tissue Healing.

TTX General Information +

ASX Code TTX
Website http://tetratherix.com
Industry/Sector Biotechnology
Market Cap ($M) 178
TTX Share Price $6.060
Day High $6.160
Day Low $5.900
Last Close $6.060
TTX Share Price Movement - ( No change )
Prices as at 16:35, 16 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Tetratherix Limited (TTX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Tetratherix Limited (TTX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Tetratherix Limited (TTX) price-sensitive announcements

TTX - Appendix 4E and Annual Report 2026
Tetratherix Limited's 2026 Annual Report reflects a strong transition towards commercializ
Tetratherix Limited (TTX)
20 Aug 2026 | 9:05 AM
TTX - Quarterly Activities/Appendix 4C Cash Flow Report
Tetratherix Limited, listed on ASX as TTX, has reported a strong cash position of AUD 34.4
Tetratherix Limited (TTX)
22 Jul 2026 | 8:24 AM
TTX - Successful Completion $15M Placement
Tetratherix Limited (ASX: TTX) has successfully secured $15 million through a strategic pl
Tetratherix Limited (TTX)
28 May 2026 | 9:22 AM
TTX - Trading Halt
On 26 May 2026, Tetratherix Limited (ASX: TTX) announced a trading halt on its securities,
Tetratherix Limited (TTX)
26 May 2026 | 9:29 AM

Tetratherix Limited (TTX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Tetratherix Limited (TTX)
ORDINARY FULLY PAID
 Health Care $179 Notice of Annual General Meeting/Proxy Form 12 Oct 2026 1:27PM $6.590 $6.060 fallen by 8.04%
Tetratherix Limited (TTX)
ORDINARY FULLY PAID
 Health Care $179 Application for quotation of securities - TTX 7 Oct 2026 4:38PM $6.630 $6.060 fallen by 8.60%
Tetratherix Limited (TTX)
ORDINARY FULLY PAID
 Health Care $179 Tegenix FDA Review Progress 6 Oct 2026 8:56AM $6.380 $6.060 fallen by 5.02%
Tetratherix Limited (TTX)
ORDINARY FULLY PAID
 Health Care $179 Notification regarding unquoted securities - TTX 2 Oct 2026 10:47AM $6.400 $6.060 fallen by 5.31%
Tetratherix Limited (TTX)
ORDINARY FULLY PAID
 Health Care $179 Line of sight ophthalmic tissue spacing US revenue 16 Sep 2026 8:33AM $6.340 $6.060 fallen by 4.42%
Tetratherix Limited (TTX)
ORDINARY FULLY PAID
 Health Care $179 Tetratherix Ships First US Polymer, Revenue Begins 31 Aug 2026 8:28AM $6.930 $6.060 fallen by 12.55%

TTX Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$9.32 -$18.40 -49.60% 0.00 0.00 0.00% 0.0%
2025A -$9.43 -$36.50 306.00% 0.00 0.00 0.00% 0.0%
2024A -$4.52 -$9.00 13.70% 0.00 0.00 0.00% 0.0%

TTX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
CSL Limited (CSL) $88,582M 0.7309 -0.4425 0.0602 11.4357 20.5111 19.3468 2.30% 2.30% 2.37%
Mesoblast Limited (MSB) $2,585M -0.4501 0.0000 0.0000 0.0000 0.0000 310.9375 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,949M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,221M -1.3893 0.0000 -0.5231 0.0000 181.5385 380.6452 0.00% 0.00% 0.00%
Tetratherix Limited (TTX) $181M -0.4959 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

TTX Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 9.82 0.00
Market 0.31 13.50 1.04 0.70
Sector 0.77 43.70 2.65 2.10

TTX Directors

Name Position Start Date
Mr William(Will) F Knox Chief Executive Officer, Executive Director 23 Aug 2021
Dr Ali Fathi Founder and CTO, Executive Director 20 Aug 2015
Ms Emma Cleary Non-Executive Chairman, Non-Executive Director 13 Mar 2025
Mr Peter Gray Non-Executive Director 15 Dec 2025
Mr John Michael Kelly Non-Executive Director 30 May 2025
Ms Gillian Shea Non-Executive Director 13 Mar 2025
Ms Atlanta Daniel Non-Executive Director 10 Apr 2025
Mr Maurizio Vecchione Non-Executive Director 21 Jan 2026

Tetratherix Limited (TTX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value

See all changes in directors' interest & trades for Tetratherix Limited (TTX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

TTX Management

Name Position
Cherie Beach CFO
Jacob Pfeffer Company Secretary
Terence Abrams Founder and COO

TTX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Tetratherix Limited (TTX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
14,097,000 (26.58%) Aftibio Nominees Pty Limited
5,569,920 (10.50%) Ryder GP Pty Ltd
4,607,884 (8.69%) Radar Ventures Limited Partnership
3,348,990 (6.31%) William Knox

TTX Calendar of Events

Date Event
19 August 2027 Report (Annual)
19 August 2027 Report (Prelim)
23 February 2027 Report (Interim)
12 November 2026 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.